Status:
COMPLETED
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
Lead Sponsor:
British Columbia Cancer Agency
Conditions:
Brain Neoplasms
Lung Neoplasms
Eligibility:
All Genders
19-90 years
Brief Summary
Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement of positron emission from radiolabelled tracer molecules. These radiotracers allow biologic processes to be ...
Detailed Description
1.0 Background \& Introduction In general, diagnostic imaging can address two issues: structure and function. One can either view structures in the body and image anatomy using structural imaging mod...
Eligibility Criteria
Inclusion
- Age 19 years or older.
- ECOG performance status 0 - 3.
- Able to provide written informed consent.
- Referred by a treating physician.
- Must meet BCCA evidence-based guidelines for FDG-PET in oncology
- Patients must be able to tolerate the physical/logistical requirements of completing a PET scan including lying flat for up to 45 minutes and tolerating intravenous cannulation for injection.
Exclusion
- Patients' blood glucose \> 11.1 mmol/L (200 mg/dL) measured by glucometer immediately prior to scan.
- Pregnancy
- Patients unable to provide informed consent.
- Patients who are medically unstable e.g. acute cardiac or respiratory distress or hypotensive
- Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
39242 Patients enrolled
Trial Details
Trial ID
NCT00207298
Start Date
June 1 2005
End Date
August 1 2015
Last Update
January 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BCCA, Vancouver Centre
Vancouver, British Columbia, Canada, V5Z 4E6